Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.49 |
| ▸ | CDC25B | P30305 | 7/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.49 |
| ▸ | CDC25A | P30304 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756405 | 1.00 | PTPN1 (0.49) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL18183914 | 1.00 | PTPN1 (0.49) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL13046915 | 0.91 | PTPN1 (0.50) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL14479459 | 0.90 | CYP19A1 (0.48) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3331695 | 0.90 | ACE (0.56) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL18183893 | 0.90 | CYP19A1 (0.48) | CTSSCTSLCTSBCTSK | |
| SCHEMBL304588 | 0.90 | ACE (0.56) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL19701644 | 0.88 | PTPN1 (0.43) | PTPN1CDC25BPTPN2CDC25APPARA | |
| SCHEMBL5358340 | 0.82 | MAPT (0.46) | PPARATACR1CTSSACEPPARG | |
| SCHEMBL18681590 | 0.82 | CYP19A1 (0.44) | PTPN1CDC25BPTPN2CDC25AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8093243-B2 | Inhibit the function of the non-structural proteins (NS5A) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-7704992-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-7659270-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PTPN1 1524/4885CDC25B 1153/4885PTPN2 1394/4885 |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PTPN1 1524/4885CDC25B 1153/4885PTPN2 1394/4885 |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PTPN1 998/4885CDC25B 1276/4885PTPN2 861/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PTPN1 1524/4885CDC25B 1153/4885PTPN2 1394/4885 |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PTPN1 1524/4885CDC25B 1153/4885PTPN2 1394/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PTPN1 1524/4885CDC25B 1153/4885PTPN2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.